Definitive Contract 75N93026C00006
Award Date 7/1/26
Potential Completion Date 6/30/29
Potential Value $4.5M
Federal Agency
Awardee
Ultimate Awardee
Not listed Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Cost Plus Fixed Fee
Place of Performance
Owings Mills, MD, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
18
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a $36,967,744.00 cost-plus-fixed-fee definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Asell, LLC for the advanced development, validation, and FDA clearance of the CellRadX point-of-care biodosimetry system. The contract is not set-aside. This contract was awarded under a Broad Agency Announcement (BAA) solicitation from the Biomedical Advanced Research and Development Authority (BARDA) seeking proposals for the advanced...
- The National Institute of Allergy and Infectious Diseases awarded a $4.5 million definitive contract to Micron Biomedical Inc. for development of radiation and nuclear medical countermeasures and biodosimetry devices on July 1, 2026, with no set-aside. The contract encompasses development of a toll-like receptor 5 agonist dissolving microneedle patch for radiation and nuclear medical applications. Place of performance is Atlanta, Georgia. The period of performance runs from July 1, 2026...
- This is a $100,361,311 cost-plus-fixed-fee contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to the non-profit research organization MRIGlobal, also known as Midwest Research Institute, for the development of "Biodosimetry High-Throughput Diagnostic Tests." The contract supports the creation of diagnostic tests to evaluate radiation exposure, which is a critical capability for public health emergency preparedness. As a prime contractor,...
- This $4,175,467 definitive cost-no-fee contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Pluri Biotech LTD, a for-profit limited liability company based in Israel, for the development of PLX-R18 cell therapy as a countermeasure for hematopoietic acute radiation syndrome. The contract, which has no set-aside designation, supports research and development efforts focused on creating safe and effective medical countermeasures to mitigate...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,624,116.99 definitive contract to the University of Wisconsin System to provide centralized dosimetry guidance and monitoring of radiation sources and irradiation protocols across institutions funded by NIAID's Radiation Nuclear Countermeasures Program (RNCP) portfolio. The contract, which has no set-aside designation, was awarded on June 1, 2020 and runs through May 31, 2025. The contractor will be responsible for...
- This is a $6,150,127.06 definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to BCN Biosciences LLC for the development of medical countermeasures to mitigate and/or treat radiation-induced lung injury after a radiological/nuclear incident. The contract has an ultimate completion date of April 30, 2019 and does not have a set-aside designation. Based on the major program code, this contract supports NIAID's efforts to develop...
- This is a $4,756,378.01 cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to SRI International, a non-profit research and development institute. The contract is for the development of a novel plasma protein biomarker panel for a radiation/nuclear triage biodosimetry device, known as the "RAPID RAD DX" project. This effort supports NIAID's mission to develop products for the assessment, diagnosis, mitigation,...
- The National Institute of Allergy and Infectious Diseases issued a delivery order to Sri International on September 22, 2016, with a ceiling value of $7.9 million for radiation and nuclear medical countermeasure product development support services under a cost-plus-fixed-fee pricing structure. The delivery order, Task Order B-2, covers animal model development and initial efficacy testing of candidate medical countermeasures, with performance at Sri International's Menlo Park, California...
- <p>The National Institute of Allergy and Infectious Diseases issued a delivery order to Sri International on September 29, 2017, with a ceiling value of $15.56 million for radiation/nuclear medical countermeasure product development support services.</p> <p>Place of performance is Menlo Park, California. The order is priced as cost-plus-fixed-fee with an ultimate completion date of December 15, 2020. No set-aside was used.</p>
- Chromologic LLC, a minority-owned small business located in Monrovia, California, was awarded a $4.88 million cost-plus-fixed-fee contract by the National Institute of Allergy and Infectious Diseases (NIAID) on July 1, 2023, for the development of MIDOS (A MicroRNA Biodosimeter). The contract, which extends through June 30, 2027, responds to NIAID's need for advanced biodosimetry approaches and medical countermeasures to assess and mitigate acute or delayed radiation injuries. The project builds...